Contract research organization ICON is turning to artificial intelligence to make clinical trials faster, according to Stock Titan, which reports that the company is adopting Microsoft Copilot to help accelerate its drug-testing work.
ICON is what the industry calls a CRO — a company that pharmaceutical and biotech firms hire to run the clinical trials that test whether new drugs are safe and effective. That work is notoriously slow and document-heavy, involving large volumes of paperwork, data and coordination across many sites and people.
Microsoft Copilot is an AI assistant built into Microsoft's software tools. The aim of bringing it into ICON's operations, per Stock Titan, is to use AI to speed up clinical trials — the kind of repetitive, text-and-data-intensive tasks where automated assistants are increasingly being deployed.
The move reflects a broader trend in the pharmaceutical industry, where companies are looking to AI to cut the time and cost of getting new medicines through testing and to market. For a CRO like ICON, faster trials can be a competitive advantage, since clients want results sooner and at lower cost.
The available reporting frames this as ICON "betting" on Microsoft's AI tools, signaling a deliberate strategic choice rather than a small experiment. Specific details on scale, timing or measurable results are not provided in the source.
Why it matters: clinical trials are one of the slowest, most expensive steps in bringing new drugs to patients, so even modest AI-driven gains in speed could ripple through how quickly treatments reach the people who need them.